Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 31, 2006

Merck & Co. Shells Out $1.1B for Sirna

  • Merck & Co. will acquire Sirna Therapeutics for a cash value of approximately $1.1 billion. At $13 per share, this amount is more than double Sirna’s closing price of $6.45 on October 30, 2006. Sirna is currently trading at $12.7 per share.
    "This is another example of Merck delivering on its strategy of aggressively pursuing biotechnology companies that complement our considerable internal research capabilities," remarks Richard N. Kender, vp of business development and corporate licensing.

    Sirna creates RNAi-based therapeutics. Its lead clinical development candidate, Sirna-027, is a chemically optimized, siRNA currently moving into Phase II development for the treatment of the wet-form of age-related macular degeneration as part of a broad collaboration with Allergan. The company also has an alliance with GlaxoSmithKline for the development of siRNA compounds for the treatment of respiratory diseases. In addition, Sirna has several programs covering a range of therapeutic areas, including infectious diseases, metabolism, CNS, and dermatology.

    Merck and Sirna expect to complete the acquisition in the first quarter of 2007. Sirna stockholders who own approximately 36% of the company’s outstanding shares have said they will support the transaction and have entered into voting agreements.

Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »